BioVie (BIVI)
(Delayed Data from NSDQ)
$0.41 USD
+0.01 (2.53%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $0.41 0.00 (-0.02%) 5:30 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BIVI 0.41 +0.01(2.53%)
Will BIVI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BIVI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIVI
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
BIVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
Other News for BIVI
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
BioVie unveils protocol design of SUNRISE-PD Phase 2 trial of NE3107
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
BioVie presents protocol design for upcoming Phase 2 trial of bezisterim